Obinutuzumab
Showing 51 - 75 of 229
Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphoid Leukemia
- Bendamustine
- +3 more
-
Dresden, Germany
- +16 more
Nov 8, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Cyclophosphamide
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Acalabrutinib, Obinutuzumab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Basking Ridge, New Jersey
- +7 more
Nov 9, 2022
Primary Focal Segmental Glomerulosclerosis Trial in Rochester (Obinutuzumab)
Recruiting
- Primary Focal Segmental Glomerulosclerosis
- Obinutuzumab
-
Rochester, MinnesotaMayo Clinic in Rochester
Dec 13, 2021
CLL Transformation Trial in Italy, Switzerland (Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax
Recruiting
- CLL Transformation
- Obinutuzumab 25 MG/ML [Gazyva]
- +2 more
-
Alessandria, Italy
- +16 more
Sep 27, 2022
Chronic Lymphocytic Leukemia Trial in Germany (Obinutuzumab, Venetoclax, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia
- Obinutuzumab
- +2 more
-
Bad Saarow, Germany
- +29 more
May 4, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in United States (Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Obinutuzumab
- Venetoclax
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Chronic Lymphocytic Leukemia Trial in Boston, Rochester, Durham (Obinutuzumab, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Obinutuzumab
- Ibrutinib
-
Boston, Massachusetts
- +3 more
Jan 3, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)
Completed
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Ibrutinib
- Obinutuzumab
-
Portland, OregonOHSU Knight Cancer Institute
Dec 10, 2021
Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, CAL-101)
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Apr 29, 2022
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Germany (Obinutuzumab)
Terminated
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Obinutuzumab
-
Bonn, Germany
- +6 more
Dec 16, 2021
Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)
Recruiting
- Follicular Lymphoma
- Venetoclax
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Nov 12, 2021
Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)
Terminated
- Mantle Cell Lymphoma
- Obinutuzumab
-
Warszawa, Poland
- +1 more
Dec 23, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- acalabrutinib
- +3 more
-
Columbus, OhioResearch Site
Mar 11, 2022
Lymphoma, Non-Hodgkin Trial in Mainz (Obinutuzumab and Pixantrone)
Completed
- Lymphoma, Non-Hodgkin
- Obinutuzumab and Pixantrone
-
Mainz, RLP, GermanyDepartment of Hematology, Oncology and Pneumology; University Me
Mar 30, 2022
Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory Trial (Glofitamab, Pirtobrutinib, Obinutuzumab)
Not yet recruiting
- Mantle Cell Lymphoma
- Mantle Cell Lymphoma Refractory
- Glofitamab
- +3 more
- (no location specified)
Apr 18, 2023
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1
Active, not recruiting
- Ann Arbor Stage II Grade 1 Follicular Lymphoma
- +12 more
- Lenalidomide
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Metastatic Colorectal Cancer Trial in Worldwide (RO7122290, Cibisatamab, Obinutuzumab)
Recruiting
- Metastatic Colorectal Cancer
- RO7122290
- +2 more
-
Toronto, Ontario, Canada
- +15 more
Jan 13, 2023
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Obinutuzumab, Rituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Venetoclax
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Dec 5, 2022
Colorectal Cancer Trial in Worldwide (Obinutuzumab, Atezolizumab, Cibisatamab)
Active, not recruiting
- Colorectal Cancer
- Obinutuzumab
- +3 more
-
Los Angeles, California
- +12 more
Aug 19, 2022
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte
Not yet recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +2 more
- Biopsy
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 15, 2023
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)
Completed
- Lymphoma, Large B-Cell, Diffuse
- Venetoclax
- Obinutuzumab
-
Graz, Austria
- +5 more
Feb 15, 2022